ターゲットリポソームドラッグデリバリー市場規模、シェア、成長分析：製品別、技術別、適応症別、エンドユーザー別、地域別 - 産業予測 2025～2032年

ターゲットリポソームドラッグデリバリー市場規模は2023年に15億5,000万米ドルと評価され、2024年の16億2,000万米ドルから2032年には23億米ドルに成長し、予測期間（2025-2032年）のCAGRは4.5%で成長する見通しです。

ターゲットリポソームドラッグデリバリー市場は、特異的かつ制御された薬物放出を可能にし、それによって副作用を最小限に抑え、治療効果を高めるドラッグデリバリー技術の進歩によって、大きな成長が見込まれています。慢性疾患の有病率の上昇と個別化医療への意欲の高まりが、市場拡大のさらなる原動力となっています。継続的な調査、戦略的パートナーシップ、ヘルスケア投資の増加も寄与しています。北米と欧州は強固なヘルスケアインフラを背景に現在市場を独占しているが、アジア太平洋地域はヘルスケアの革新と患者層の拡大に注力しており、有望な機会を提供しています。主な動向には、新規製剤の開発や標的治療の探求などがあり、この分野のダイナミックで急速な進化を浮き彫りにしています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析

ターゲットリポソームドラッグデリバリー市場規模：製品別& CAGR（2025-2032）

• 市場概要
• リポソームパクリタキセル
• リポソームドキソルビシン
• リポソームアムホテリシンB
• その他

ターゲットリポソームドラッグデリバリー市場規模：技術別& CAGR（2025-2032）

• 市場概要
• ステルスリポソーム技術
• 非PEG化リポソーム技術
• デポフォームリポソーム技術

ターゲットリポソームドラッグデリバリー市場規模：適応症別& CAGR（2025-2032）

• 市場概要
• 真菌性疾患
• 疼痛管理
• がん治療薬
• その他

ターゲットリポソームドラッグデリバリー市場規模：エンドユーザー別& CAGR（2025-2032）

• 市場概要
• 病院
• クリニック
• 調査室
• その他

ターゲットリポソームドラッグデリバリー市場規模：地域別& CAGR（2025-2032）

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• Gilead Sciences, Inc.（United States）
• Pacira BioSciences, Inc.（United States）
• Spectrum Pharmaceuticals, Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Johnson & Johnson Services, Inc.（United States）
• Ipsen Pharma（France）
• Celsion Corporation（United States）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Acrotech Biopharma, Inc.（United States）
• Astellas Pharma Inc.（Japan）
• Alnylam Pharmaceuticals, Inc.（United States）
• Arbutus Biopharma Corporation（Canada）
• Camurus AB（Sweden）
• Acuitas Therapeutics（Canada）

結論と提言

Targeted Liposomes Drug Delivery Market size was valued at USD 1.55 billion in 2023 and is poised to grow from USD 1.62 billion in 2024 to USD 2.3 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The Targeted Liposomes Drug Delivery Market is poised for significant growth, driven by advancements in drug delivery technologies that enable specific and controlled drug release, thereby minimizing side effects and enhancing therapeutic effectiveness. The rising prevalence of chronic diseases and a growing appetite for personalized medicine further fuel this market expansion. Continued research, strategic partnerships, and increased healthcare investments are also contributing factors. North America and Europe currently dominate the market due to robust healthcare infrastructure, while the Asia-Pacific region offers promising opportunities with its focus on healthcare innovation and expanding patient demographics. Key trends include the development of novel formulations and the exploration of targeted therapies, highlighting a dynamic and rapidly evolving landscape in this sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Targeted Liposomes Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Targeted Liposomes Drug Delivery Market Segments Analysis

Global Targeted Liposomes Drug Delivery Market is segmented by Product, Technology, Indication, End User and region. Based on Product, the market is segmented into Liposomal Paclitaxel, Liposomal Doxorubicin, Liposomal Amphotericin B and Others. Based on Technology, the market is segmented into Stealth Liposome Technology, Non-PEGylated Liposome Technology and DepoFoam Liposome Technology. Based on Indication, the market is segmented into Fungal Diseases, Pain Management, Cancer Therapeutics and Others. Based on End User, the market is segmented into Hospitals, Clinics, Research Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Targeted Liposomes Drug Delivery Market

The increasing demand for personalized and precision medicine significantly propels the growth of the targeted liposomes drug delivery market. Targeted liposomes serve as advanced delivery vehicles, providing controlled release and reducing side effects, ultimately enhancing therapeutic effectiveness. Additionally, the rising prevalence of chronic diseases, particularly cancer, has heightened interest in innovative drug delivery technologies such as targeted liposomes. This trend underscores the importance of these specialized systems in developing more efficient and tailored treatment options, reflecting a broader shift towards more individualized healthcare solutions aimed at improving patient outcomes and optimizing therapeutic interventions.

Restraints in the Targeted Liposomes Drug Delivery Market

A significant restraint facing the Targeted Liposomes Drug Delivery market is the high cost associated with advanced liposomal formulations and technologies, which can limit accessibility for some stakeholders. Additionally, the regulatory landscape presents challenges, with varying approval processes across different regions, potentially leading to delays in bringing new liposomal products to market. These barriers not only hinder innovation but also restrict the ability to capitalize on the therapeutic benefits that targeted liposome delivery systems could offer, ultimately affecting the overall growth and development of the market. Consequently, these factors pose hurdles for stakeholders aiming to invest and participate in this sector.

Market Trends of the Targeted Liposomes Drug Delivery Market

The Targeted Liposomes Drug Delivery market is witnessing a notable trend driven by the increasing emphasis on personalized medicine. As healthcare shifts toward individualized treatment approaches, there is a growing demand for customized liposomal formulations tailored to meet the specific needs of patients. Innovations in liposomal technology, including the development of smart and stimuli-responsive liposomes, are enhancing the precision of drug delivery. These advancements not only improve therapeutic efficacy but also minimize side effects, positioning targeted liposomes as a pivotal component in the future of personalized therapeutics. This focus on customization is likely to propel market growth and stimulate further research in the sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Targeted Liposomes Drug Delivery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Liposomal Paclitaxel
• Liposomal Doxorubicin
• Liposomal Amphotericin B
• Others

Global Targeted Liposomes Drug Delivery Market Size by Technology & CAGR (2025-2032)

• Market Overview
• Stealth Liposome Technology
• Non-PEGylated Liposome Technology
• DepoFoam Liposome Technology

Global Targeted Liposomes Drug Delivery Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Fungal Diseases
• Pain Management
• Cancer Therapeutics
• Others

Global Targeted Liposomes Drug Delivery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals
• Clinics
• Research Laboratories
• Others

Global Targeted Liposomes Drug Delivery Market Size & CAGR (2025-2032)

• North America (Product, Technology, Indication, End User)
  • US
  • Canada
• Europe (Product, Technology, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pacira BioSciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Spectrum Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ipsen Pharma (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celsion Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acrotech Biopharma, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arbutus Biopharma Corporation (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Camurus AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acuitas Therapeutics (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations